TIGIT and neoplasm: Consistent with the scRNA-seq analysis, Fc-active TIGIT monoclonal antibodies drove increased cell surface expression of MHC-II on tumour myeloid cells, including dendritic cells, macrophages and monocytes (Fig. 5a).